Somatostatin-14 is a natural cyclic peptide hormone derived from the preprohormone, somatostatin. It is a somatostatin (SST) receptor agonist that binds to SST1, SST2, SST3, SST4, and SST5 (IC50s = 0.22, 0.10, 0.28, 1.23, and 0.30 nM, respectively, in CCL39 cells expressing human recombinant receptors). It inhibits cAMP accumulation induced by forskolin in CCL39 cells expressing human recombinant SST1, SST2, SST3, SST4, and SST5 (EC50s = 6.16, 4.37, 17.38, 2.95, and 4.67 nM, respectively). Somatostatin-14 inhibits the release of growth hormone, prolactin, thyrotropin, glucagon, and insulin, as well as other signaling molecules.
[1] D J HADJIDAKIS. Differences between somatostatin-28 and somatostatin-14 with respect to their biological effects in healthy humans and acromegalics.[J]. Clinical physiology and biochemistry, 1986, 4 6: 372-383.
[2] S SIEHLER D H K Seuwen. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 1999, 360 5: 488-499. DOI:
10.1007/s002109900141[3] S SIEHLER D H. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 1999, 360 5: 510-521. DOI:
10.1007/s002109900143[4] GILLIES G. Somatostatin: the neuroendocrine story.[J]. Trends in pharmacological sciences, 1997, 18 3: 87-95. DOI:
10.1016/s0165-6147(96)01032-2[5] IAN M P JOSEPH. A model for integrative study of human gastric acid secretion.[J]. Journal of applied physiology, 2003, 94 4: 1602-1618. DOI:
10.1152/japplphysiol.00281.2002
